(Submitted for publication January 22, 1962 ; accepted March 9, 1962) The amino acid L-histidine is obtained by man primarily from dietary protein. The essential need for this amino acid, however, has not been demonstrated conclusively (1) . Previous studies have indicated that the major pathways of utilization of L-histidine are by way of incorporation into body protein, excretion into the urine, and metabolism to glutamic acid. It is believed that the pertinent mammalian pathway follows the reactions outlined in Figure 1 (2) (3) (4) . Prior to our initial report (5) of the compounds shown in Figure 1 , histidine, a-formiminoglutamic acid (FiGlu), and glutamic acid had been definitively identified in the urine of man. Urocanic acid (UA) had been identified in the urine of small mammals (2) and tentatively identified chromatographically in the urine of man (6) . Imidazolonepropionic acid has not been identified in urine as yet, although a metabolic oxidation product derived from this intermediate, hydantoin-5-propionic acid, has been identified in rat urine (7) . Since our original report, characterizing the occurrence of UA in the urine of man (5) , McIsaac and Page (8) have described the identification of UA in the urine of a patient with hepatic coma, and similarly UA has been identified by Whitehead and Arnstein in a patient with kwashiorkor (9) .
FiGlu excretion has been studied in recent years in patients with folic acid deficiency (10) (11) (12) and treated with folic acid antagonists (13) . It has been found that such patients, particularly when given loading doses of histidine, excrete increased amounts of this metabolite in the urine. Small amounts of folic acid correct this defect. The role of vitamin B12 (14) and the behavior of patients with pernicious anemia after histidine loading have not been completely defined. Several patients with vitamin B12 deficiency, apparently uncomplicated by folic acid deficiency, have had increased amounts of FiGlu in the urine with (15) or without (16) histidine loading, with an accentuation of the defect in two patients given folic acid (15) . However, an increased FiGlu excretion after histidine loading does not always occur in uncomplicated vitamin B12 deficiency (10) . It has been reported by Carter, Schaffner and Heller (17) that FiGlu excretion in patients with hepatic cirrhosis is increased after histidine loading. Our studies were initiated on a malnourished patient with a macrocytic anemia, who had been referred to the National Institutes of Health. This patient was given a loading dose of histidine and excreted large amounts of UA, a phenomenon previously observed in the urine of rats fed ethionine (18) . The specific identification of UA and the excretion of UA and FiGlu in normal patients, patients with variable diagnoses, and patients with chronic alcoholism and liver disease are the subject of this paper.
METHODS
The 25 subjects comprising this study were: 1) normal subjects (group A, nos. 1-6) who were laboratory personnel employed at the Clinical Center, National Institutes of Health; 2) patients (group B, nos. 7-16) who had no history or definite evidence of primary hepatocellular disease; and 3) patients (group C, nos. 17-25) who had varying types of diffuse cellular liver disease, primarily as a consequence of chronic alcoholism. The clinical diagnoses and pertinent laboratory data are summarized in Table I Determination of urocanic acid and formiminoglutamic acid. A procedure previously described for the determination of FiGlu and UA, the metabolites of histidine, in rat urine (18) has now been modified and applied to the determination of these metabolites in human urine. The method involves the treatment of aliquants of urine with an active extract of chicken liver and subsequent microbiological assay of the reaction mixture. The net reaction is the conversion of ring carbon-2 of UA or the formimino-carbon of FiGlu into the N-5 formyl group of citrovorum factor (N'-formyl tetrahydrofolic acid).
The application of the method to human urine is now described. Twvo aliquants, an untreated sample and an autoclaved sample, of each specimen were assayed. The autoclaved samples were prepared as follows. To 1 ml of urine, 1 drop of 1.0 M potassium hydroxide was added and the urine autoclaved at 15 (19) but leaves the UA intact.
The dialyzed extract of chicken liver was that previously described (20) . Because This method for the determination of these histidine metabolites is valid when applied to rat urine (18) . The portion of the procedure concerned with the estimation of UA in human urine has not been tested extensively, but in this study it has been demonstrated that, if urine specimens show the presence of UA by the above 1 Since no inhibitors of folic acid reductase were present in the urine specimens employed, the preincubation period of liver extract and reducing supplement was omitted (21). The first patient (Subject 17) was a 45-year-old negro female who was admitted May 9, 1959, for evaluation of a macrocytic anemia. At the time of admission she complained of burning feet of 3 weeks' duration. Since age 20 the patient had drunk large quantities of alcohol. From 1953 until 1956 she was hospitalized for pulmonary tuberculosis and discharged improved, after a right lobectomy. During the 3 years prior to admission she had continued to drink and had eaten irregularly. She had progressively lost weight from approximately 120 to 77 pounds in the previous year. For several weeks before admission she had noted extreme weakness and had fainted several times; just before coming to the hospital she found it difficult to walk because of burning feet and weakness. Except for rather frequent episodes of nausea she had no gastrointestinal symptoms or other history of significance. Her physical examination at the time of admission revealed her to be emaciated but in no acute distress. Her temperature was 38°C, pulse 100 per minute, respiration 20 per minute, and blood pressure 90/60 mm Hg. Findings in the right chest were consistent with her history of healed tuberculosis. The liver was palpable 3 cm below the right costal margin. The spleen was not palpable. The neurological examination revealed a decrease in vibration sense and hypesthesia of a stocking distribution extending to the midthigh bilaterally.
Additional pertinent laboratory data included: bone marrow-megaloblastoid erythroid hyperplasia not considered diagnostic of pernicious anemia; erythrocyte in- after fell to 7.1 g per 100 ml. The mean cell volume reached a low of 88 ;4'. The patient's hematological indices and serum iron rapidly responded to oral ferrous sulfate therapy which was begun 3 months after admission. At 8 months the values were: hemoglobin 13.7 g per 100 ml; hematocrit 42 mm; erythrocyte count 4.6 million per mm3; serum iron 92 ,ug per 100 ml; and total iron-binding capacity 306 Atg per 100 ml. In addition, the serum proteins slowly rose to 4.6 g per 100 ml albumin and 4.0 g per 100 ml globulin. Within a 4-week period after institution of a regular diet, the sulfobromophthalein retention had fallen from an initial 44 per cent to 3 per cent. During the 8-month period of study the patient stated that she did not drink alcoholic beverages and that she ate regularly. Her weight rose from 77 to 113 pounds. The FiGlu and UA excretion data are presented in Figure 2 . The final pertinent diagnoses were: chronic alcoholism complicated by malnutrition, nutritional megaloblastic anemia, severe nutritional liver dysfunction, peripheral neuropathy, and iron deficiency.
The second patient (Subject 19), a 50-year-old white male, was admitted October 8, 1959, with complaints of nervousness, nausea, and weakness following prolonged alcoholic intake. He stated that he had been an alcoholic since the age of 17. He had previously been treated medically for complications of his liver dysfunction, including jaundice, fluid retention, and bleeding esophageal varices. At the time of admission the patient appeared chronically ill. Pertinent findings included an enlarged, tender, smooth liver, 7 cm below the right costal margin in the midclavicular line. The spleen was just palpable below the left costal margin. Jaundice was visible. There was minimal stocking hypesthesia of both feet. The pertinent laboratory data are seen in Table I .
While on a regular hospital diet the patient's excretion of FiGlu and UA was followed with and without oral loading with histidine. Attempts were made to vary his response to histidine loading by adding methionine and folic acid (Figure 3 ). He slowly improved and was discharged. Shortly thereafter he bled from his esophageal varices and a portocaval anastamosis was performed at another hospital. Six weeks after surgery he again became jaundiced and was told that he had developed serum hepatitis. He gave no history of alcohol intake during this period. He was readmitted to the Clinical Center on September 28, 1960, for re-evaluation of his liver function and response to histidine loading (see Figure 3) . The liver remained tender and firm and was palpable 8 cm below the right costal margin in the midclavicular line. The spleen was not palpable. Slight hypesthesia of the feet was present. The laboratory data are summarized below the previous data in Table I .
The final pertinent diagnoses were: Laennec's cirrhosis, portal hypertension, esophageal varices, and chronic alcoholism.
Isolation of urocanic acid from urine of Subject 17. Urine was collected for 24 hours after the ingestion of a loading dose of histidine and placed in storage at -10°C. The urine was collected on day 12 ( Figure 2 ). The total volume was 634 ml, of which 350 ml was available for the attempt at isolation.
An aliquant of urine containing 83 umoles of UA (biological assay) was passed through a column (3.5 x 20.0 cm) of Dowex-50H. The resin was washed with 700 ml of H20 and 1 L of 1.1 N sulfuric acid, and the activity was eluted with 1.95 N sulfuric acid. Fractions of 100 ml were collected, and the activity in each was determined by bioassay in samples freed of sulfate with barium carbonate. Fractions 11 through 18, containing 63.8 ,umoles of UA, were combined and freed of sulfate with barium carbonate and barium hydroxide. The sulfate-free solution was passed through 15 ml of Dowex-50H packed in a 100-ml buret. The resin was washed with 100 ml of 0.55 N sulfuric acid followed by 100 ml of 1.1 N sulfuric acid. A gradient was developed by passing 2.78 N sulfuric acid through 90 ml of H2O, and 10-ml fractions were collected. Each fraction was examined spectrophotometrically (ultraviolet) for UA. The active fractions (30 through 40) were combined, freed of sulfate with barium carbonate and adjusted to pH 7.0 with barium hydroxide.
The combined fractions were passed through 9.5 ml Dowex-l-acetate contained in a 100-ml buret. Normal acetic acid passed through a head of 45 ml of water was used to elute the UA from the resin. Five-ml fractions were collected and examined spectrophotometrically. The UA (32,moles; 6.3 mg as dihydrate) was found in fractions 7 through 11. These fractions were combined, concentrated to 1.0 ml, and stored for 24 hours at -10°C. Upon thawing, a white crystalline precipitate settled out.
It was collected on a sintered glass funnel, and dried in vacuo. The yield was 4.0 mg.
The ultraviolet absorption spectra of the isolated sample were consistent with those of UA. In 0. The infrared absorption spectra (Nujol mull) of the recrystallized isolated material and synthetic UA-2H2O were identical (Figure 4) . On Schleicher and Schuell paper (no. 598) the isolated material and synthetic sample moved at essentially the same rate in three solvent sys- 24 -hour, 3,000-ml urine sample. An aliquot of urine, 22 ml, was passed through 9.5 ml of Dowex-1-acetate. The resin was washed with 15 ml of H.0 and eluted with 40 ml of 0.5 M acetic acid. The eluate was concentrated to dryness in vacuo, the residual solids extracted with 1 ml H20, and the extract stored 24 hours' at -10°C. After thawing, the insoluble materials were rejected by filtration. The filtrate was acidified with 2 drops of 2.0 M hydrochloric acid and extracted five times with 10-ml portions of butanol. The butanol extracts were combined, evaporated to dryness, and the residue dissolved in 1 ml HO. The final ex- It is noteworthy that two of the three patients in The nine patients in group C had laboratory this group with significantly elevated FiGlu ex-evidence of significant liver dysfunction (Table I) . cretion had clinically evident malnutrition. After Jaundice was present in four patients, impaired administration of histidine, the mean excretion of sulfobromophthalein excretion in five, abnormal UA among the normal group was 11.7 ± 2.3 cephalin flocculation in five, and elevated serum ,umoles per day in contrast to a mean excretion glutamic oxalacetic transaminase values in four ,umoles per day, whereas FiGlu excretion remained normal, increasing from 3 to 19 /moles with histidine administration. In this and the previous patient the clinical status suggested a concomitant nutritional deficiency, including that of folic acid and iron. These were the only two instances in which UA excretion exceeded that of FiGlu after a histidine load. In the remainder of the subjects the control period output of either UA, or FiGlu, or both exceeded the mean normal excretion by more than 2 SD. After histidine loading (Table IV) group C excreted significantly greater amounts of UA or FiGlu than either group A or B (p < 0.05).
The difference in excretions due to a histidine load was similarly increased in group C (p < 0.05). When the combined excretions of UA and FiGlu after histidine or the combined difference due to histidine in group C are compared with group A or B, a significant increase is again noted (p < 0.025).
The two patients described in detail (17 and 19) were studied at length. Their excretions of UA and FiGlu are seen in Figures 2 and 3 . Subject 17 showed a rapid increase in her ability to metabolize UA. This coincided with her clinical improvement during hospitalization while she was on a regular hospital diet. On days 44 to 46 the patient's ability to respond normally to an oral histidine load was almost complete. The daily excretion of UA and FiGlu was followed for 18 days. An indication of the consistency of the data obtained from the urinary excretion of these metabolites with and without the administration of oral histidine is seen in Figure 2 .
Subject 19 ( Figure 3 ) had severe Laennec's cirrhosis. The impairment in degradation of FiGlu was severe, however; there was only slight impairment in the ability of this patient to metabolize UA. During a prolonged evaluation there was gradual improvement in the ability to metabolize both of these products. Methionine In Figure 5 the UA and FiGlu excretion rates after histidine are plotted in four time-periods. Mkost of the UA and FiGlu appear during the first 12 hours as a result of the oral histidine load given at the beginning of the urine collection. It is interesting to note that the peak of UA excretion occurs before that of FiGlu. One would expect this result from a knowledge of the metabolic pathway of histidine as outlined in Figure 1 . Actually, most of the increased excretion of these metabolites seems to occur during the first 6 hours after an oral histidine load of 3.0 g.
DISCUSSION
The fact that urocanic acid is an intermediate in the mammalian degradation of histidine (Figtire 1 ) seems well substantiated (2) . The existence of a similar pathway has been presumed in man. While the excretion of a-formiminoglutamic acid, another metabolite of histidine, is known as a breakdown product of histidine in man and is known to be increased after oral histidine loading of patients who have folic acid deficiency (11, 15) , IUA had not been definitively identified before the initial report of this work (5) . The isolation and identification of UA, presented herein, leaves no doubt of its presence in man, documenting further the existence in man of the degradative pathway of histidine metabolism shown in Figure 1 . In this sequence of reactions the ring carbon-2 of histidine becomes the formimino group of FiGlu via UA. The formimino group is then transferred to tetrahydrofolic acid, a reaction catalyzed by formiminoglutamic acid transferase, ultimately to enter the pool of metabolically active one-carbon fragments as a derivative of N-10-formyltetrahydrofolic acid. The excretion of FiGlu in folic acid deficiency (11, 15) , pernicious anemia (15, 16) , or folic acid antimetabolite therapy (13, 21) is believed to be due to a lack of tetrahydrofolic acid receptor for the formimino group.
Liver disease was simultaneously reported in abstracts by Carter and colleagues (17) Figure 2) . impaired ability to metabolize histidine. In view of the known relationship between folic acid deficiency and FiGlu excretion, and previous observations indicating that some cirrhotic patients may be deficient in folic acid (24) (25) (26) , it is reasonable to conclude that folic acid deficiency may also play a role in the excretion of FiGlu in the patients reported herein. That two patients in group B who excreted larger amounts of FiGlu were undernourished, and the response to an adequate diet in five patients (nos. 17, 19, 21, 22, and 24) would bear this out. Nevertheless, the fact that restoration of adequate nutrition did not result in a complete return to normal of FiGlu excretion in patients in this study or in that of Jandl and Lear, and Carter and colleagues (25, 26) suggests that liver dysfunction of sufficient degree per se may interfere with the formiminoglutamic acid transferase reaction. Although the lack of marked FiGlu excretion despite profoundly abnormal liver function tests in serum hepatitis also suggests that malnutrition may play a significant role in the abnormal excretion of FiGlu in cirrhosis, the basic differences in the two pathologic processes and the chronicity of cirrhosis make this conclusion tenuous at best.
The low UA excretion in the patients of group B after histidine loading was unexpected and unexplained. The most likely explanation is that it is due to chance, in view of the small number of patients. Another possibility is that the group as a whole was in negative nitrogen balance, and an increased fraction of the administered histidine was utilized anabolically. If this were so, one would expect FiGlu excretion to be lower also, which was not the case.
In view of the observations in rats that methionine abolishes the abnormal FiGlu excretion due to folic acid or cyanocobalamin deficiency, and increases the utilization of histidine ring carbon-2 (14, 27) , methionine was fed to Subject 19. Since the excretion of FiGlu did not change significantly even after histidine administration, one might present this as evidence against an increased FiGlu excretion caused by deficiency of folic acid or vitamin B,,. Such reasoning is highly speculative, however, since the cause of the "methionine effect" is poorly understood.
The interesting role played by an increased UA excretion in patients subjected to a metabolic load of histidine concurrent with liver dysfunction and probable folic acid deficiency is difficult to reconcile in view of the absence of known effects of folic acid on this portion of the metabolic pathway. If this were due to a buildup of metabolic products along the pathway as a consequence of folic acid deficiency, then a predominance of FiGlu would be expected. This did not occur in the patients who had a marked UA excretion (nos. 17 and 18). Two independent observations of UA excretion in patients with severe liver dysfunction have been recently reported (8, 9) . In the first, a patient in hepatic coma is reported to have UA in the urine. No other clinical information is given. In the second, a series of patients with kwashiorkor is reported. Such patients have severe protein depletion and an apparent secondary liver dysfunction. No hematological findings are reported. One might also expect a folic acid deficiency to be present. The question arises: Does UA excretion represent a lack of the enzyme urocanase due to liver disease or is there some as yet unknown cofactor necessary for the metabolism of this product? Again, the multiplicity of etiologic and pathologic factors in cirrhosis and kwashiorkor makes answering these questions difficult. The observation that the UA excretion decreased, but not to normal levels, in Patients 17 and 19 suggests that both factors-liver damage and specific cofactor deficiency-may be involved. The improvement in both UA and FiGlu excretion might well be a result simply of reversal of fatty infiltration which accompanied better nutrition and abstinence from alcohol.
The presence of multiple variables operating in this series of patients indicates that the mechanism underlying these defects in histidine metabolism will require correlation of the excretion of these metabolic products with liver function and biopsy studies in a wider variety of liver diseases if, indeed, the mechanism can be elucidated in man at all. In the meantime, the correlations and responses to therapy shown in this small series offer some hope that excretion of urocanic acid and formiminoglutamic acid as parameters of liver function may have some prognostic, if not diagnostic, value.
SUM MARY
Urocanic acid (UA) has been definitively identified as a urinary metabolite in man. Methodologies for the quantification of UA and a-formiminoglutamic acid (FiGlu) in human urine are described. Both UA and FiGlu excretion are increased after oral histidine loading in normal control subjects and in patients with lhepatocellular disease. The response to loading in patients with hepatocellular disease is exaggerated. The complexity of the pathophysiological process in patients with liver disease is such that conclusions relative to the roles of folic acid deficiency, hepatocellular damage, and decreased enzyme activities in increasing UA and FiGlu excretions are speculative. The daily excretions of UA and FiGlu with and without oral histidine are reported in two subjects in detail.
